Clinical Trial Update: 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or Trastuzumab [Phase 2]

View source ↗

Summary

A Phase 2 study comparing afatinib, lapatinib, and trastuzumab in locally advanced breast cancer has completed, with results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Gilotrif (Afatinib)
• HERCEPTIN (trastuzumab)
• Tykerb (lapatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Breast Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-10-17